Skip to content

NovoCure NVCR Gross Profit

Gross Profit at other companies

Boston Scientific logo
Boston ScientificBSX
$3.61B+12.6%
Medtronic logo
MedtronicMDT
$6.41B+10.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$28.93M+338%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$1.2M-60.2%
ALN
Alnylam PharmaceuticalsALNY
$959.66M+83.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.64B-36.7%
Enterprise value$1.59B-36.3%
P/S2.4×-1.7×

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's gross profit?
NovoCure (NVCR) reported gross profit of $135.13M in Q1 2026.
How has NovoCure's gross profit changed year-over-year?
NovoCure's gross profit increased by 16.0% year-over-year, from $116.47M to $135.13M.
What is the long-term trend for NovoCure's gross profit?
Over 4 years (2021 to 2025), NovoCure's gross profit has grown at a 3.8% compound annual growth rate (CAGR), from $420.15M to $488.47M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.